Tysabri Production Continues Ahead Of Possible Reintroduction

Biogen Idec is manufacturing Tysabri at a slower rate since marketing of the MS therapy was suspended in late February, CEO Mullen says. Continued manufacturing is "prudent at this point," the firm says. Production pause provides an opportunity to enhance manufacturing facilities and processes.